SUPPORTING INFORMATION

Hybrid Inhibitors of Malarial Dihydrofolate Reductase with Dual Binding Modes That Can Forestall Resistance
Bongkoch Tarnchompo,‡ Penchit Chitnumsun,‡ Aritsara Jaruwat, Philip J. Shaw, Jarunee Vanichtanankul, Sinothai Poen, Roonglawan Rattanajak, Chayaphat Wongsombat, Aunchalee Tonsomboon,† Sasithorn Decharuangsilp, Tosapol Anukunwithaya, Uthai Arwon, Sumalee Kamchonwongpaisan, and Yongyuth Yuthavong*

National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathumthani 12120, Thailand
‡These authors contributed equally to this work.
†Faculty of Medical Technology, Rangsit University, Pathumthani 12000, Thailand

*To whom the correspondence should be addressed: Prof. Yongyuth Yuthavong.
Tel. +6681 005 9293; fax: +662 564 7140. E-mail: yongyuth@biotec.or.th.
TABLE OF CONTENTS

RESULT .......................................................................................................................... S1
  Co-crystal Structures of the Hybrid Inhibitors with hDHFR ....................................... S1
MATERIALS AND METHODS ...................................................................................... S1
Chemistry Experimental Section .................................................................................. S1
  Chemical Synthesis of Rigid-Flexible Hybrid Compounds ....................................... S2
  Chemical Synthesis of Rigid-Rigid Hybrid Compounds .......................................... S6
Biological Experimental Section .................................................................................. S9
  Kinetic Analysis ........................................................................................................ S9
  In vitro Antimalarial and Cytotoxicity Analysis ......................................................... S9
  Assessment of Possible PfDHFR Resistance Mutations against BT1 ....................... S9
Structural Biology Experimental Section ..................................................................... S10
  Crystallization, Structure Determination and Analysis ............................................ S10
Figure S1. Binding modes of BT1 and BT2 with hDHFR ............................................. S12
Table S1. Data collection and refinement statistics of PfDHFR-TS wild-type (TM4) and quadruple mutant (V1/S) in complex with hybrid inhibitors BT1, BT2 and BT3 .......... S13
Table S2. Data collection and refinement statistics of hDHFR in complex with BT1 and BT2 .................................................................................................................. S14
REFERENCES .............................................................................................................. S15
RESULT

Co-crystal Structures of the Hybrid Inhibitors with hDHFR. Compounds BT1 and BT2 co-crystal structures with hDHFR were determined in order to visualize the difference in the binding modes of the hybrid inhibitors. For hDHFR, the enzyme accommodates BT1 and BT2 in a similar binding mode to those observed in the wild-type PfDHFR. The rigid part of BT1 binds deep in the pocket interacting with E30, equivalent to PfDHFR D54 (Figure S1A). In order to avoid steric clash with T56 (equivalent to PfDHFR S108), the flexible end of BT2 is docked at the E30 site and the phenyl ring of the rigid end forms a tilted π-π interaction with the F31 side chain, equivalent to PfDHFR M55 (Figure S1B). In addition, subtle movement (1 Å) of the hydrophobic cleft at residues 60-64 (IPEKN) was observed in the binding of BT2. However, the pyrimidine rings of both BT1 and BT2 protrude out of the pocket space, resulting in weaker inhibition in the human enzyme (Figure S1C). In contrast, all three hybrid inhibitors stay within PfDHFR enzyme space and the van der Waals interaction of F116 (Figure 2).

MATERIALS AND METHODS

Chemistry Experimental Section

General Procedure: All reagents were purchased from Aldrich, Fluka and Merck, and used without further purification, unless otherwise indicated. Solvents were purchased from Aldrich, Fluka, Fisher and RCI Labscan, and where necessary dried immediately prior to use by distillation from standard drying reagents. Melting points were recorded using an Electrothermal IA9100 apparatus and are uncorrected. 1H NMR spectra were recorded using a Bruker Avance III 400 (400 MHz), or a Bruker Avance III HD (500 MHz) spectrometer. 13C NMR spectra were recorded using a Bruker Avance III 400 (100 MHz), or a Bruker Avance III HD (125 MHz) spectrometer. Chemical shifts (δ) are reported in parts per million (ppm) and are referenced to the appropriate residual solvent peak. Electrospray ionization high resolution mass spectra were measured on a Bruker microTOF mass spectrometer in positive ion mode.
I. Chemical Synthesis of Rigid-Flexible Hybrid Compounds

Scheme S1  Synthetic strategy employed for hybrid compound

Reagents and conditions: (a) NaH, THF, -78 °C then EtCOOMe, 90 °C; (b) CH₂N₂, dioxane/MeOH; (c) guanidine, DMSO/MeOH, 90-100 °C; (d) cyclohexene, 10% Pd/C, 65 °C; (e) LiOH·H₂O, DMF, 3-bromo-1-propanol, rt; (f) Ph₃P, DIAD, DMF, rt; (g) HCl, H₂O

A. Rigid Diaminopyrimidine Part

1. Synthesis of β-ketonitrile (1)

A solution of phenylacetonitrile 1-1 (781 mg, 3.30 mmol) in THF (15 mL) was slowly added into a cooled suspension of sodium hydride (153 mg, 3.50 mmol, 55% dispersion in mineral oil) in THF (5 mL) at -78 °C and stirred under N₂ for 30 min. A reaction mixture was then heated at 90 °C for 10 min followed by an addition of methyl propionate (1.7 mL, 17.50 mmol) in one portion. The reaction mixture was allowed to stir at 90 °C for 20 min and then quenched with saturated NH₄Cl aqueous solution (50 mL) at 0 °C. The product was extracted with CH₂Cl₂ (3×100 mL) and the organic layer was washed with brine (50 mL), dried (MgSO₄), and evaporated to
dryness under reduced pressure. Purification of the crude product by silica gel column chromatography (hexanes/CH₂Cl₂ 45:55) afforded the pure compound.

2-(3-(Benzyloxy)phenyl)-3-oxopentanenitrile (1a): a white solid, 40%; mp 69-71 °C (CH₂Cl₂/hexanes). ¹H NMR (400 MHz, CDCl₃, δ): 7.45-7.30 (m, 6H), 6.99 (m, 3H), 5.08 (s, 2H), 4.65 (s, 1H), 2.68-2.48 (m, 2H), 1.02 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃, δ): 199.4, 159.5, 136.3, 131.2, 130.7, 128.7, 128.2, 127.6, 120.4, 116.3, 115.7, 114.5, 70.2, 50.7, 33.1, 7.6. HRMS-ESI (m/z): [M+Na]⁺ calcd for C₁₈H₁₇NNaO₂, 302.1151; found: 302.1154.

2-(4-(Benzyloxy)phenyl)-3-oxopentanenitrile (1b): a white solid, 45%; mp 134-135 °C (CH₂Cl₂/hexanes). ¹H NMR (400 MHz, CDCl₃, δ): 7.43-7.34 (m, 5H), 7.29 (d, J = 8.6 Hz, 2H), 7.01 (d, J = 8.6 Hz, 2H), 5.07 (s, 2H), 4.63 (s, 1H), 2.72-2.51 (m, 2H), 1.03 (t, J = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃, δ): 199.7, 159.4, 136.3, 130.1, 129.2, 128.7, 128.2, 127.5, 122.0, 116.5, 115.8, 70.1, 49.8, 33.0, 7.6. HRMS-ESI (m/z): [M+Na]⁺ calcd for C₁₈H₁₇NNaO₂, 302.1151; found: 302.1156.

2. Synthesis of rigid diaminopyrimidine (2-1)

Diazomethane gas was passed into a cold solution of β-ketonitrile 1 (886 mg, 3.00 mmol) in dioxane/MeOH (6:1, 35 mL) and the reaction mixture was stirred at rt for 8 h. Removal of solvent under reduced pressure gave the desired enol-ether, which was dried under vacuum and used in the next step without purification. A mixture of enol-ether and guanidine (195 mg, 3.30 mmol) in DMSO/EtOH (8:2, 25 mL) was heated at 90-100 °C under N₂ for 6 h. After removal of solvents under vacuum, water (100 mL) was added to a residue and extracted with CH₂Cl₂ (3×100 mL). The combined organic extracts were washed with water (50 mL), brine (50 mL), dried (MgSO₄) and evaporated under reduced pressure. Purification of the residue by silica gel column chromatography (CH₂Cl₂/MeOH 94:6) yielded the pure product 2-1.

5-(3-(Benzyloxy)phenyl)-6-ethylnicotinamide (2-1a): a white solid, 75%; mp 201-202 °C (MeOH). ¹H NMR (400 MHz, DMSO-d₆, δ): 7.45 (d, J = 7.2 Hz, 2H), 7.38 (dd, J = 7.6, 7.1 Hz, 2H), 7.34-7.30 (m, 2H), 6.99 (dd, J = 8.2, 2.2 Hz, 1H), 6.80 (s, 1H), 6.75 (d, J = 7.5 Hz, 1H), 5.90 (s, 2H, NH₂), 5.54 (br s, 2H, NH₂), 5.11 (s, 2H), 2.09 (q, J = 7.5 Hz, 2H), 0.93 (t, J = 7.5 Hz, 3H). ¹³C NMR (100 MHz, DMSO-d₆, δ): 166.3, 162.0, 161.9, 158.6, 137.4, 137.1, 130.0, 128.4, 127.8, 127.7, 123.0, 116.7, 113.8, 106.4, 69.2, 27.4, 13.2. HRMS-ESI (m/z): [M+H]⁺ calcd for C₁₉H₂₁N₃O, 321.1710; found, 321.1711.
5-(4-(Benzyloxy)phenyl)-6-ethylpyrimidine-2,4-diamine (2-1b): a white solid, 75%; mp 229-230 °C (MeOH). \(^1\)H NMR (400 MHz, DMSO-\(d_6\), \(\delta\)): 7.48 (d, \(J = 7.1\) Hz, 2H), 7.42 (m, 2H), 7.36-7.33 (m, 1H), 7.08 (m, 4H), 5.80 (s, 2H, NH\(_2\)), 5.39 (br s, 2H, NH\(_2\)), 5.11 (s, 2H), 2.10 (q, \(J = 7.6\) Hz, 2H), 0.95 (t, \(J = 7.6\) Hz, 3H). \(^13\)C NMR (100 MHz, DMSO-\(d_6\), \(\delta\)): 167.4, 163.0, 162.6, 158.2, 137.8, 132.4, 129.1, 128.8, 128.6, 128.5, 115.8, 106.8, 70.0, 28.2, 13.9. HRMS-ESI (m/z): [M+H]+ calcd for C\(_{19}\)H\(_{21}\)N\(_4\)O, 321.1710; found, 321.1716.

3. Synthesis of rigid diaminopyrimidine (2)

A mixture of diaminopyrimidine 2-1 (320 mg, 1.00 mmol), 10% Pd/C (100 mg) and cyclohexene (2 mL) in dioxane/MeOH (1:1, 10 mL) was heated at 65 °C under N\(_2\) for 6 h. The Pd/C was removed by Celite filtration and the filtrate was concentrated under reduced pressure to give a solid, which was then recrystallized from dioxane/MeOH to yield a white solid 3.

5-(3'-Hydroxyphenyl)-6-ethylpyrimidine-2,4-diamine (2a): a white solid; 85%, mp 248-249 °C. \(^1\)H NMR (400 MHz, DMSO-\(d_6\), \(\delta\)): 9.47 (s, 1H, OH), 7.21 (t, \(J = 7.8\) Hz, 1H), 6.72 (dd, \(J = 8.0, 1.8\) Hz, 1H), 6.59-6.54 (m, 2H), 5.83 (s, 2H, NH\(_2\)), 5.41 (br s, 2H, NH\(_2\)), 2.12 (q, \(J = 7.5\) Hz, 2H), 0.97 (t, \(J = 7.5\) Hz, 3H). \(^13\)C NMR (100 MHz, DMSO-\(d_6\), \(\delta\)): 166.2, 162.0, 161.9, 157.6, 137.2, 129.9, 121.0, 117.2, 114.2, 106.7, 27.4, 13.3. HRMS-ESI (m/z): [M+H]+ calcd for C\(_{12}\)H\(_{15}\)N\(_4\)O, 231.1240; found, 231.1243.

5-(4'-Hydroxyphenyl)-6-ethylpyrimidine-2,4-diamine (2b): a white solid; 80%, mp 247-249 °C (dec). \(^1\)H NMR (400 MHz, DMSO-\(d_6\), \(\delta\)): 9.44 (s, 1H, OH), 6.95 (d, \(J = 8.4\) Hz, 2H), 6.81 (d, \(J = 8.4\) Hz, 2H), 5.79 (s, 2H, NH\(_2\)), 5.38 (br s, 2H, NH\(_2\)), 2.10 (q, \(J = 7.5\) Hz, 2H), 0.94 (t, \(J = 7.5\) Hz, 3H). \(^13\)C NMR (100 MHz, DMSO-\(d_6\), \(\delta\)): 166.6, 162.4, 161.8, 156.4, 131.5, 126.0, 115.8, 106.4, 27.4, 13.2. HRMS-ESI (m/z): [M+H]+ calcd for C\(_{12}\)H\(_{15}\)N\(_4\)O, 231.1240; found, 231.1234.

B. Flexible Diaminopyrimidine Part

4. Synthesis of flexible diaminopyrimidine (3)

A suspension of 5-hydroxy-6-ethyl-2,4-diaminopyrimidine (3-1) (771 mg, 5.00 mmol) and lithium hydroxide monohydrate (629 mg, 15.00 mmol) in DMF (5 mL) was stirred at rt for 30 min. 3-Bromo-1-propanol (0.45 mL, 5.00 mmol) was then added, and the reaction mixture was continued to stir at rt for 8 h. Removal of DMF under vacuum gave crude product, which was purified by crystallization from water to yield pure 5-(3'-hydroxypropyloxy)-6-ethyl-2,4-
diaminopyrimidine (3) as a white solid (690 mg; 65%, mp 182-183 °C). $^1$H NMR (400 MHz, DMSO-$d_6$, $\delta$): 6.13 (s, 2H, NH$_2$), 5.55 (s, 2H, NH$_2$), 4.65 (br s, 1H, OH), 3.66 (t, $J = 6.1$ Hz, 2H), 3.56 (t, $J = 6.1$ Hz, 2H after D$_2$O exchange), 2.36 (q, $J = 7.5$ Hz, 2H), 1.82 (quin, $J = 6.1$ Hz, 2H), 1.06 (t, $J = 7.5$ Hz, 3H). $^{13}$C NMR (100 MHz, DMSO-$d_6$, $\delta$): 160.4, 159.7, 158.9, 129.0, 70.0, 58.1, 33.0, 24.2, 13.4. HRMS-ESI (m/z): [M+H]$^+$ calcd for C$_9$H$_{17}$N$_4$O$_2$, 213.1346; found, 213.1345.

C. Rigid-Flexible Hybrid Compounds

5. Synthesis of rigid-flexible hybrid compounds

To a solution of compound 2 (230 mg, 1.00 mmol), compound 3 (265 mg, 1.25 mmol) and triphenylphosphate (302 mg, 1.15 mmol) in DMF (3 mL) was added diisopropyl azodicarboxylate (0.23 mL, 1.15 mmol) at rt and stirred under N$_2$ for 8 h. Removal of solvents under vacuum gave an off-white solid, which was then recrystallized from water, hexanes/MeOH, MeOH/water, and dioxane/MeOH systems, respectively to yield a white solid. Flash silica gel column chromatography (CH$_2$Cl$_2$/MeOH 90:10) gave the pure compound.

5-[3-[3-(2,4-Diamino-6-ethyl-5-pyrimidinyl)oxy]propoxy]phenyl]-6-ethylpyrimidine-2,4-diamine (BT1): a white solid; 30%, mp 208-210 °C. $^1$H NMR (500 MHz, DMSO-$d_6$, $\delta$): 7.35 (t, $J = 8.1$ Hz, 1H), 6.94 (dd, $J = 8.3$, 1.6Hz, 1H), 6.75-6.73 (m, 2H), 6.11 (s, 2H, NH$_2$), 5.86 (s, 2H, NH$_2$), 5.57 (s, 2H, NH$_2$), 5.44 (br s, 2H, NH$_2$), 4.16 (m, 2H), 3.76 (t, $J = 6.1$ Hz, 2H), 2.32 (q, $J = 7.5$ Hz, 2H), 2.14-2.10 (m, 4H), 0.99 (t, $J = 7.5$ Hz, 3H), 0.96 (t, $J = 7.5$ Hz, 3H). $^{13}$C NMR (100 MHz, DMSO-$d_6$, $\delta$): 166.1, 161.7, 161.6, 159.6, 158.6, 157.9, 137.1, 129.6, 128.4, 122.4, 116.3, 113.3, 106.5, 68.8, 64.2, 29.0, 27.0, 23.3, 12.5, 11.9. HRMS-ESI (m/z): [M+H]$^+$ calcd for C$_{21}$H$_{29}$N$_8$O$_2$, 425.2408; found, 425.2409.

5-[4-[3-(2,4-Diamino-6-ethyl-5-pyrimidinyl)oxy]propoxy]phenyl]-6-ethylpyrimidine-2,4-diamine (BT2): a white solid; 35%, mp 257-258 ºC. $^1$H NMR (500 MHz, DMSO-$d_6$, $\delta$): 7.09 (d, $J = 8.3$ Hz, 2H), 7.01 (d, $J = 8.3$ Hz, 2H), 6.11 (s, 2H, NH$_2$), 5.81 (s, 2H, NH$_2$), 5.56 (s, 2H, NH$_2$), 5.39 (br s, 2H, NH$_2$), 4.19 (t, $J = 5.8$ Hz, 2H), 3.79 (t, $J = 5.8$ Hz, 2H), 2.35 (q, $J = 7.5$ Hz, 2H), 2.16 (m, 2H), 2.11 (q, $J = 7.5$ Hz, 2H), 1.03 (t, $J = 7.5$ Hz, 3H), 0.95 (t, $J = 7.5$ Hz, 3H). $^{13}$C NMR (125 MHz, DMSO-$d_6$, $\delta$): 166.6, 162.3, 161.9, 159.8, 159.0, 158.1, 157.5, 131.6, 128.7, 127.8,
114.9, 106.1, 68.9, 64.2, 29.2, 27.4, 23.5, 13.1, 12.6. HRMS-ESI (m/z): [M+H]+ calcd for C$_{21}$H$_{29}$N$_8$O$_2$, 425.2408; found, 425.2418.

6. Synthesis of 5-[4-{(2,4-Diamino-6-ethyl-5-pyrimidinyl)oxy}propoxy]phenyl]-6-ethylpyrimidine-2,4-diamine dihydrochloride (BT2S)

A mixture of BT2 (100 mg, 0.24 mmol) and concentrated hydrochloric acid (0.04 mL, 0.48 mmol) in water (1 mL) was stirred at rt for 1 h. The resulting precipitates were collected by filtration and washed with water to yield pure BT2S as a white solid (105 mg, 95%). $^1$H NMR (400 MHz, DMSO-$d_6$, $\delta$): 12.76 (s, 1H, NH$^+$), 12.60 (s, 1H, NH$^+$), 8.35 (s, 1H, NH), 8.14 (s, 1H, NH), 7.87 (s, 1H, NH), 7.48 (br s, 4H, 2×NH$_2$), 7.18 (d, $J = 8.6$ Hz, 2H), 7.07 (d, $J = 8.6$ Hz, 2H), 6.70 (s, 1H, NH), 4.18 (t, $J = 5.9$ Hz, 2H), 3.89 (t, $J = 6.0$ Hz, 2H), 2.53 (q, $J = 7.5$ Hz, 2H), 2.24-2.19 (m, 4H), 1.13 (t, $J = 7.6$ Hz, 3H), 1.05 (t, $J = 7.6$ Hz, 3H). $^{13}$C NMR (100 MHz, DMSO-$d_6$, $\delta$): 164.3, 160.9, 158.4, 154.7, 153.8, 147.1, 131.4, 127.4, 122.8, 115.2, 107.7, 70.5, 64.1, 28.7, 23.3, 19.7, 12.0, 11.5. HRMS-ESI (m/z): [M-2HCl+H]$^+$ calcd for C$_{21}$H$_{29}$N$_8$O$_2$, 425.2408; found, 425.2403.

II. Chemical Synthesis of Rigid-Rigid Hybrid Compounds

Scheme S2  Synthesis of rigid-rigid hybrid compound

Reagents and conditions: (a) K$_2$CO$_3$, 1,3-dibromopropane, DMF; (b) NaBH$_4$, MeOH; (c) SOCl$_2$, CH$_2$Cl$_2$; (d) NaCN, DMF; (e) NaH, THF, -78 °C then EtCOOMe, 90 °C; (f) CH$_2$N$_2$, dioxane/MeOH; (g) guanidine, DMSO/MeOH, 90-100 °C; (h) HCl, H$_2$O
1. **Synthesis of 4,4-[1,3-propanediylbis(oxy)]bisbenzaldehyde (4-2)**

To a mixture of 4-hydroxybenzaldehyde (4-1) (1.83 g, 15.00 mmol) and anhydrous potassium carbonate (4.15 g, 30.00 mmol) at 0 °C, dry DMF (50 mL) was added and continued stirring at 0 °C for 3 h. The reaction mixture was then heated to 90 °C for 1 h and followed by an addition of 1,3-dibromopropane (1.5 mL, 7.50 mmol) in one portion. After stirring for 1 h and removal of DMF under vacuum, water (100 mL) was added and extracted with CH₂Cl₂ (3×100 mL). Drying (MgSO₄) and evaporation under reduced pressure yielded crude product, which was purified by silica gel column chromatography (hexanes/CH₂Cl₂ 70:30) to give the desired product as a white solid (3.20 g; 75%, mp 137-139 °C, lit.² mp 134-135 °C). ¹H NMR (400 MHz, CDCl₃, δ): 9.89 (s, 2H, CHO), 7.84 (d, J = 8.7 Hz, 4H), 7.02 (d, J = 8.7 Hz, 4H), 4.26 (t, J = 6.0 Hz, 4H), 2.35 (quin, J = 6.0 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃, δ): 190.9, 164.0, 132.2, 130.4, 115.0, 64.8, 29.2. HRMS-ESI (m/z): [M+Na]⁺ calcd for C₁₇H₁₆NaO₄, 307.0941; found, 307.0948.

2. **Synthesis of 4,4-[1,3-propanediylbis(oxy)]bisbenzyl alcohol (4-3)**

To a suspension of aldehyde 4-2 (2.84 g, 10.00 mmol) in THF/MeOH (25 mL, 4:1), NaBH₄ (1.14 g, 30.00 mmol) was added portionwise at 0 °C and then left stirring at rt for 6 h. The resulting reaction mixture was concentrated under reduced pressure and then cooled to 0 °C, ice-water was carefully added dropwise followed by acidification with dil. HCl to provide a white solid. Recrystallization with water and THF gave the pure alcohol 4-3 as white solid (2.60 g; 90%, mp 154-155 °C, lit.³ mp 145-146 °C). ¹H NMR (400 MHz, DMSO-d₆, δ): 7.21 (d, J = 8.3 Hz, 4H), 6.89 (d, J = 8.4 Hz, 4H), 5.05 (t, J = 5.6 Hz, 2H, 2xOH), 4.40 (d, J = 5.6 Hz, 4H), 4.10 (t, J = 6.2 Hz, 4H) 2.14 (quin, J = 6.2 Hz, 2H). ¹³C NMR (100 MHz, DMSO-d₆, δ): 157.4, 134.6, 127.9, 114.1, 64.2, 62.5, 28.7. HRMS-ESI (m/z): [M+Na]⁺ calcd for C₁₇H₂₀NaO₄, 311.1254; found, 311.1257.

3. **Synthesis of 4,4-[1,3-propanediylbis(oxy)]bisbenzyl chloride (4-4)**

To a solution of benzyl alcohol 4-3 (1.50 g, 5.20 mmol) in CH₂Cl₂ (15 mL) was added dropwise SOCl₂ (1.1 mL, 15.60 mmol) at 0 °C under N₂, and the mixture was then heated at reflux for 5 h. Neutralization with saturated solution of NaHCO₃, extraction with CH₂Cl₂ (3×100 mL) and evaporation to dryness yielded a solid which was recrystallized with diethyl ether to give the desired product 4-4 as an off-white solid with 90% purity as determined by ¹H NMR and used directly in the next step (1.06 g; 65%, mp 128-130 °C, lit.⁴ mp 126-127 °C). ¹H NMR (400 MHz,
CDCl₃, δ: 7.30 (d, J = 8.5 Hz, 4H), 6.88 (d, J = 8.5 Hz, 4H), 4.56 (s, 4H), 4.16 (t, J = 6.0 Hz, 4H), 2.29-2.22 (m, 2H). ¹³C NMR (100 MHz, CDCl₃, δ): 158.9, 130.1, 114.5, 64.4, 46.3, 29.2.

4. Synthesis of 4,4-[1,3-Propanediylbis(oxy)]bisbenzeneacetonitrile (4-5)

A mixture of benzyl chloride 4-4 (1.63 g, 5.00 mmol) and sodium cyanide (490 mg, 10.00 mmol) in DMF (5 mL) was heated at 100 ºC for 5 h. After removal of DMF, water (100 mL) was added to a residue and followed by extraction with CH₂Cl₂ (3×100 mL). Drying (MgSO₄) and evaporation under reduced pressure gave crude product, which was purified by flash chromatography (hexanes/CH₂Cl₂ 65:35) to afford 4-5 as a white solid (1.15 g; 75%, mp 119-121 ºC, lit.⁴ mp 112-113 ºC). ¹H NMR (400 MHz, CDCl₃, δ): 7.22 (d, J = 8.5 Hz, 4H), 6.90 (d, J = 8.5 Hz, 4H), 4.15 (t, J = 6.0 Hz, 4H) 3.68 (s, 4H), 2.26 (quin, J = 6.0 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃, δ): 158.9, 130.1, 114.5, 64.4, 46.3, 29.2.

5. Synthesis of 1,3-Di(4-(1-cyano-2-oxobutyl)phenoxy)propane (4)

Following the procedure as described for compound 1, compound 4-5 (1.07 g, 3.50 mmol) was alkylated with methyl propionate (1.7 mL, 17.50 mmol) to produce 4 as a white solid (659 mg, 45%; mp 126-128 ºC). ¹H NMR (400 MHz, CDCl₃, δ): 7.22 (d, J = 8.5 Hz, 4H), 6.90 (d, J = 8.5 Hz, 4H), 4.62 (s, 2H), 4.16 (t, J = 5.9 Hz, 4H), 2.70-2.50 (m, 4H), 2.27 (quin, J = 5.9 Hz, 2H), 1.02 (t, J = 7.2 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃, δ): 199.7, 159.4, 129.2, 121.9, 116.5, 115.4, 64.3, 49.8, 33.0, 29.0, 7.6. HRMS-ESI (m/z): [M+Na]+ calcd for C₂₅H₂₆N₂NaO₄, 441.1785; found, 441.1793.

6. Synthesis of 5,5-[1,3-Propanediylbis(oxy-4,1-phenylene)]-bis[6-ethyl]-pyrimidine-2,4-diamine (BT3)

Following the procedure as described for compound 2-1, compound 4 (627 mg, 1.50 mmol) was converted to the corresponding enol-ether, which was then condensed with guanidine (222 mg, 3.75 mmol). Crystallization with hot water and dioxane/MeOH yielded the pure hybrid BT3 as a white solid (488 mg, 65%, mp 270-272 ºC (dec)). ¹H NMR (500 MHz, DMSO-d₆, δ): 7.07 (d, J = 8.6 Hz, 4H), 7.01 (d, J = 8.6 Hz, 4H), 5.82 (s, 4H, 2×NH₂), 5.40 (br s, 4H, 2×NH₂), 4.17 (t, J = 6.0 Hz, 4H), 2.21 (quin, J = 6.1 Hz, 2H), 2.09 (q, J = 7.5 Hz, 4H), 0.94 (t, J = 7.5 Hz, 6H). ¹³C
NMR (125 MHz, DMSO-\textit{d}_6, \delta): 167.0, 162.8, 162.3, 158.0, 132.1, 128.3, 115.4, 106.6, 64.5, 29.2, 27.9, 13.6. HRMS-ESI (\textit{m/z}): [M+H]^+ calcd for C_{27}H_{33}N_{8}O_{2}, 501.2721; found, 501.2723.

7. Synthesis of 5,5-[1,3-Propanediylbis(oxy-4,1-phenylene)]-bis[6-ethyl]-pyrimidine-2,4-diamine dihydrochloride (BT3S)

Following the procedure as described for BT2S, BT3S was obtained as a white solid (108 mg; 94%, mp >300 °C (dec)). \textsuperscript{1}H NMR (500 MHz, DMSO-\textit{d}_6, \delta): 12.72 (s, 2H, 2×NH\textsuperscript{+}), 8.12 (s, 2H, NH\textsubscript{2}), 7.18 (d, J = 8.6 Hz, 4H), 7.08 (d, J = 8.6 Hz, 4H), 6.71 (s, 2H, 2×NH\textsubscript{2}), 4.19 (t, J = 6.0 Hz, 4H), 2.25-2.18 (m, 6H), 1.04 (t, J = 7.6 Hz, 6H). \textsuperscript{13}C NMR (125 MHz, DMSO-\textit{d}_6, \delta): 164.0, 158.4, 156.1, 131.6, 123.8, 115.2, 107.5, 64.0, 28.6, 24.2, 12.5. HRMS-ESI (\textit{m/z}): [M-2HCl+H]^+ calcd for C_{27}H_{33}N_{8}O_{2}, 501.2721; found, 501.2736.

Biological Experimental Section

Kinetic Analysis. DHFR activity was determined spectrophotometrically by measuring the rate of reduction of NADPH at 340 nm using \(\varepsilon_{340}\) of 12,300 M\textsuperscript{-1}cm\textsuperscript{-1}. Kinetics studies were performed as described previously.\textsuperscript{5}

\textit{In vitro} Antimalarial and Cytotoxicity Analysis. \textit{P. falciparum} strains TM4/8.2, K1CB1, W2, CSL-2 and V1/S carrying DHFR wild-type, C59R+S108N, N51I+C59R+S108N, C59R+S108N+I164L and N51I+C59R+S108N+I164L, respectively were maintained continuously in human erythrocytes in RPMI1640 supplemented with 25 mM HEPES, pH 7.4, 0.2% NaHCO\textsubscript{3}, 40 µg mL\textsuperscript{-1} gentamicin and 8% human serum at 37 °C under 3% CO\textsubscript{2}. \textit{In vitro} antimalarial activity was determined using a modified Microdilution Radioisotope Technique.\textsuperscript{5} Cytotoxicity tests against African green monkey kidney fibroblast (Vero cells) were performed using the sulforhodamine B (SRB) assay.\textsuperscript{6}

Assessment of Possible PfDHFR Resistance Mutations against BT1. PfDHFR genes were PCR-amplified using error-prone PCR conditions as described in Chusacultanachai et al.\textsuperscript{7} Plasmids containing the pET17b backbone and cloned synthetic genes for expression of PfDHFR bearing wild-type; S108N single; C59R+S108N double; N51I+C59R+S108N triple and N51I+C59R+S108N+I164L quadruple pyrimethamine-resistance mutations as described in Sirawarporn et al\textsuperscript{8} were used as templates for error-prone PCR. The error-prone PCR products
obtained from each plasmid template were combined in a DNA shuffling reaction. The mutagenized, DNA-shuffled PCR product was then cloned into the pET17b plasmid via unique HindIII and NdeI restriction sites and transformed into BL21(DE3) Escherichia coli by electroporation. The transformed cells were plated out on 20 plates of M9 minimal medium agar plates supplemented with ampicillin (100 µg mL\(^{-1}\)) and trimethoprim (2 µM). Approximately 1.5\(\times\)10\(^5\) colonies were obtained. Twenty colonies were randomly picked and plasmid DNA purified by alkaline lysis. Plasmid DNA was sequenced using the Single Pass DNA Sequencing service (First BASE Laboratories, Sdn Bhd, Malaysia). Each of the plasmid sequences had unique nucleotide variations, thus demonstrating that the original library has a complexity of approximately 1.5\(\times\)10\(^5\) PfDHFR variants. Furthermore, each variant possesses sufficient DHFR activity to support the growth of the surrogate cell in which the endogenous DHFR is inhibited by trimethoprim. Plasmid DNA was extracted and purified from the pooled bacterial colonies to generate library DNA. Library DNA was re-transformed into E. coli for drug selection. Selection of antifolate-resistant variants was done as follows. Approximately 10 ng of library DNA was transformed into BL21(DE3) E. coli by electroporation. The transformed cells were plated out on M9 minimal medium agar plates supplemented with ampicillin (100 µg mL\(^{-1}\)), trimethoprim (2 µM) and BT1 (100 or 200 µM). Previous testing of surrogate cells transformed with plasmids expressing wild-type or N51I+C59R+S108N+I164L quadruple mutant PfDHFR showed that 100 µM BT1 is completely inhibitory to the growth of these variants.

Five BT1 resistant colonies on the plate with 100 µM BT1 and nine resistant colonies from the plate with 200 µM BT1 were picked and plasmid DNA extracted for sequencing. All plasmids shared the same nucleotide sequence, in which novel resistance mutations K97N, S108T and E199V were identified in addition to the pyrimethamine-resistance mutations N51I, C59R and I164L.

**Structural Biology Experimental Section**

**Crystallization, Structure Determination and Analysis.** PfDHFR-TS enzymes were expressed, purified and crystallized as described previously.\(^{11,12}\) Co-crystals of BT1, BT2 and BT3 with wild-type and quadruple mutant PfDHFR-TS were obtained from a microbatch method. Diffraction data for the flash cooled co-complex crystals were cryo-collected at the NSRRC beamline 13B1.
of Taiwan, ROC. Data processing was performed with the HKL-2000 software package\textsuperscript{13} and programs of the CCP4 suite.\textsuperscript{14} Structural phases were solved by molecular replacement using PHASER\textsuperscript{15} in the CCP4 suite with PfDHFR-TS pdb codes 1J3I and 1J3K. Structure refinement and adjustment were performed with REFMAC5\textsuperscript{16} and COOT.\textsuperscript{17,18} Parameter files of inhibitors BT1, BT2 and BT3 for refinement was generated with LIBCHECK. The structures were validated in PROCHECK.\textsuperscript{19} PYMOL (http://www.pymol.org) was used for molecular graphics.

Human DHFR enzyme was expressed, purified and crystallized as described previously.\textsuperscript{20} Co-crystals of BT1 and BT2 with hDHFR were obtained from hanging drop method at 24 °C. Paratone-N oil (Hampton Research) was used as a cryoprotectant. Diffraction data of BT1/hDHFR was collected using Bruker MicroSTAR X-ray generator equipped with marccd detector at Synchrotron Light Research Institute (SLRI, Public Organization) and processed with automar suite. Data of BT2/hDHFR was collected using a Bruker-Nonius FR591 X-ray generator equipped with a κCCD detector and processed with HKL2000.\textsuperscript{13} Molecular replacement with pdb code 4DDR as template using MOLREP\textsuperscript{21} and refinement using REFMAC5\textsuperscript{16} were performed in CCP4 suite.\textsuperscript{14} The model was built using COOT\textsuperscript{17,18} and validated using RAMPAGE.\textsuperscript{22} Crystallographic statistics of hDHFR were shown in Table S2.
Figure S1. Binding modes of BT1 and BT2 with hDHFR. (A) BT1 and (B) BT2 binding with hDHFR. (C) Overlay of co-complex BT1 (orange) and BT2 (green) structures of hDHFR. The flexible end of BT1 binds in the pocket by expulsion of three water molecules of BT2/hDHFR structure, while only one water molecule of BT1/hDHFR structure is displaced by the rigid end of BT2. Water molecules are shown as spheres. Hydrogen bonding interactions are highlighted as dashed lines in black and $\pi-\pi$ interaction is drawn as a double dashed line.
Table S1. Data collection and refinement statistics of PfDHFR-TS wild-type (TM4) and quadruple mutant (V1/S) in complex with hybrid inhibitors BT1, BT2 and BT3

| Parameters                        | TM4-BT1     | TM4-BT2     | TM4-BT3     | V1/S-BT1    | V1/S-BT2    | V1/S-BT3    |
|-----------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|
| **Data Collection**               |             |             |             |             |             |             |
| X-ray source                      | BL13B1,NSRRC| BL13B1,NSRRC| BL13B1,NSRRC| BL13B1,NSRRC| BL13B1,NSRRC| BL13B1,NSRRC|
| Wavelength (Å)                    | 1           | 1           | 1           | 1           | 1           | 1           |
| Space group                       | P22,21      | P22,21      | P22,21      | P22,21      | P22,21      | P22,21      |
| **Unit-Cell Parameters**          |             |             |             |             |             |             |
| a (Å)                             | 56.29       | 58.48       | 57.56       | 58.45       | 59.71       | 59.24       |
| b (Å)                             | 154.25      | 157.28      | 157.17      | 157.17      | 157.11      | 158.90      |
| c (Å)                             | 163.62      | 165.74      | 165.61      | 165.53      | 166.43      | 167.60      |
| resolution (Å)                    | 30.0-2.38 (2.47-2.38) | 30.0-2.20 (2.28-2.20) | 30.0-2.35 (2.43-2.35) | 30.0-2.38 (2.47-2.38) | 30.0-2.45 (2.54-2.45) | 30.0-2.60 (2.69-2.60) |
| total reflections                 | 305,891     | 368,942     | 328,077     | 287,436     | 260,095     | 241,231     |
| unique reflections                | 57,573      | 77,753      | 61,414      | 58,782      | 54,414      | 46,152      |
| completeness (%)                  | 98.4 (98.4) | 98.8 (90.6) | 96.8 (84.7) | 94.5 (97.1) | 93.4 (90.3) | 93.8 (93.1) |
| redundancy                        | 5.3 (5.0)   | 4.4 (3.4)   | 5.3 (4.2)   | 4.0 (3.8)   | 4.6 (4.3)   | 3.3 (3.1)   |
| Mean <I/hkl>                      | 24.5 (5.0)  | 37.8 (4.0)  | 31.5 (2.9)  | 28.9 (4.4)  | 24.7 (2.7)  | 14.7 (3.1)  |
| Rmerge (%)                        | 6.6 (33.7)  | 3.4 (28.8)  | 4.4 (39.0)  | 4.5 (25.3)  | 5.0 (40.5)  | 7.8 (39.6)  |
| **Refinement**                    |             |             |             |             |             |             |
| Rfree (%)                         | 19.2/24.8   | 19.1/24.3   | 19.7/24.3   | 19.6/25.5   | 20.3/29.1   | 21.1/26.6   |
| No. of Atoms/Average B-factors (Å²)| 9,429/53.6  | 9,807/40.5  | 9,888/35.7  | 9,241/51.6  | 9,958/36.4  | 9,492/65.1  |
| Protein                           | 8,880/55.3  | 8,917/40.3  | 9,044/35.5  | 8,762/51.4  | 9,102/36.4  | 9,132/65.3  |
| Ligand BT1/BT2/BT3                | 627/67.6    | 627/69.0    | 735/58.6    | 626/66.5    | 627/57.3    | 745/65.9    |
| Rmsd from Ideal                   |             |             |             |             |             |             |
| bond length (Å)                   | 0.013       | 0.011       | 0.011       | 0.012       | 0.012       | 0.016       |
| bond angle (deg)                  | 1.966       | 1.508       | 1.542       | 1.580       | 1.604       | 1.770       |
| Ramachandran Plot                 |             |             |             |             |             |             |
| favored (%)                       | 87.8        | 90.1        | 88.6        | 87.8        | 87.9        | 87.4        |
| allowed (%)                       | 12.0        | 9.9         | 11.2        | 12.2        | 12.1        | 12.7        |
| outlier (%)                       | 0.2         | 0.2         | 0.2         | 0.2         | 0           | 0           |
| PDB ID code                       | 6A2K        | 6A2M        | 6A2O        | 6A2L        | 6A2N        | 6A2P        |

*Values in parentheses are for the highest resolution shells. \( R_{merge} = \frac{\sum_{hkl}(I_{hkl}) - \langle I(hkl) \rangle}{\sum_{hkl}\langle I(hkl) \rangle} \), where \( I(hkl) \) is the intensity of an individual reflection and \( \langle I(hkl) \rangle \) is the mean intensity of symmetry-equivalent reflections. \( R_f = \frac{\sum_{hkl}|F_{obs}(hkl)| - |F_{calc}(hkl)|}{\sum_{hkl}|F_{obs}(hkl)|} \), where \( F_{obs} \) and \( F_{calc} \) are the observed and calculated structure-factor amplitudes, respectively. \( R_{free} \) was calculated in the same manner as \( R_f \) but using only a 10% unrefined subset of the reflection data.
Table S2. Data collection and refinement statistics of hDHFR in complex with BT1 and BT2

| Data collection | hDHFR–BT1 | hDHFR–BT2 |
|-----------------|-----------|-----------|
| X-ray source    | MicroSTAR | FR591     |
| Wavelength (Å)  | 1.5418    | 1.5418    |
| Space group     | H3        | H3        |
| Unit-Cell Parameters | a=b=82.942 | a=b=84.755 |
|                 | c=77.489  | c=77.726  |
| Resolutiona (Å) | 30-2.06 (2.13-2.06) | 50-1.85 (1.92-1.85) |
| Total reflections| 44,185    | 44,797    |
| Unique reflections| 12,165    | 17,677    |
| Completeness (%)| 99.6 (96.6) | 99.3 (99.7) |
| Redundancy      | 3.62 (3.27) | 2.5 (2.5) |
| <l/σ(l)>        | 7.8 (2.4)  | 17.3 (3.9) |
| Rmerge b (%)     | 4.82 (19.46) | 4.7 (25.8) |

Refinement

| Rf/Rfree (%)c | 17.17 (24.27) | 18.97 (23.75) |
| No. of Atoms/Average | 1752/28.35 | 1742/22.81 |
| B-factors (Å2) |        |        |
| Protein        | 1502/27.52 | 1502/22.50 |
| BT1            | 31/30.93   | -        |
| BT2            | -          | 31/20.02 |
| NAP            | 48/27.61   | 48/16.49 |
| SO4            | 15/60.08   | -        |
| Water          | 156/33.01  | 161/28.10 |
| R.m.s. deviation |        |        |
| Bond lengths (Å) | 0.0099 | 0.0097 |
| Bond angles (°)  | 1.490 | 1.533 |
| Ramachadran Plot |        |        |
| favored (%)    | 98.4 | 98.4 |
| allowed (%)    | 1.6  | 1.6  |
| outlier (%)    | 0.0  | 0.0  |
| PDB ID code    | 6A7C | 6A7E |

aValues in parentheses are for the highest resolution shell. bRmerge = Σhkl|I(hkl) − ⟨I(hkl)⟩|/ΣhklΣI(hkl), where I(hkl) is the intensity of an individual reflection and ⟨I(hkl)⟩ is the mean intensity of symmetry-equivalent reflections. cRf = Σhkl|Fobs| − |Fcalc|/Σhkl|Fobs|, where Fobs and Fcalc are the observed and calculated structure-factor amplitudes, respectively. Rfree was calculated in the same manner as Rf but using only a 10% unrefined subset of the reflection data.
REFERENCES

(1) Lee, J.; Lee, J. H.; Kim, S. Y.; Perry, N. A.; Lewin, N. E.; Ayres, J. A.; Blumberg, P. M. 2-Benzyl and 2-Phenyl-3-Hydroxypropyl Pivalates as Protein Kinase C Ligands. *Bioorg. Med. Chem.* **2006**, *14*, 2022-2031.

(2) Kueny-Stotz, M.; Brouillard, R.; Chassaing, S. Four-Step Route to Novel Bisflavylium Dications - First Synthesis of Phloroglucinol-Type Derivatives. *Synlett.* **2012**, 2053-2058.

(3) Baddeley, G.; Vickars, M. A. Interdependence of Molecular Conformation and Conjugation in Aromatic Ethers. Part V. *J. Chem. Soc.* **1963**, 765-770.

(4) Hager, G. P.; Liu, W. C. Symmetrical Bifunctional Analogs of Pharmacodynamically Active Substances. *J. Am. Pharm. Assoc. Am. Pharm. Assoc.* **1953**, *42*, 9-13.

(5) Kamchonwongpaisan, S.; Quarrell, R.; Charoensetakul, N.; Ponsinet, R.; Vilaivan, T.; Vanichtanankul, J.; Tarnchompoo, B.; Sirawaraporn, W.; Lowe, G.; Yuthavong, Y. Inhibitors of Multiple Mutants of *Plasmodium falciparum* Dihydrofolate Reductase and their Antimalarial Activities. *J. Med. Chem.* **2004**, *47*, 673-680.

(6) Vichai, V.; Kirtikara, K. Sulforhodamine B Colorimetric Assay for Cytotoxicity Screening. *Nat. Protoc.* **2006**, *1*, 1112-1116.

(7) Chusacultanachai, S.; Thiensathit, P.; Tarnchompoo, B.; Sirawaraporn, W.; Yuthavong, Y. Novel Antifolate Resistant Mutations of *Plasmodium falciparum* Dihydrofolate Reductase Selected in *Escherichia coli*. *Mol. Biochem. Parasitol.* **2002**, *120*, 61-72.

(8) Sirawaraporn, W.; Sathitkul, T.; Sirawaraporn, R.; Yuthavong, Y.; Santi, D. V. Antifolate-Resistant Mutants of *Plasmodium falciparum* Dihydrofolate Reductase. *Proc. Natl. Acad. Sci. U.S.A.* **1997**, *94*, 1124-1129.

(9) Stemmer, W. P. C. Rapid Evolution of a Protein in vitro by DNA Shuffling. *Nature* **1994**, *370*, 389-391.

(10) Feliciello, I.; Chinali, G. A Modified Alkaline Lysis Method for the Preparation of Highly Purified Plasmid DNA from *Escherichia coli*. *Anal. Biochem.* **1993**, *212*, 394-401.

(11) Chitnumsub, P.; Yuvaniyama, J.; Vanichtanankul, J.; Kamchonwongpaisan, S.; Walkinshaw, M. D.; Yuthavong, Y. Characterization, Crystallization and Preliminary X-ray Analysis of Bifunctional Dihydrofolate Reductase-Thymidylate Synthase from *Plasmodium falciparum*. *Acta Crystallogr. Sect. D: Biol. Crystallogr.* **2004**, *60*, 780-783.
(12) Yuvaniyama, J.; Chitnumsub, P.; Kamchonwongpaisan, S.; Vanichthananakul, J.; Sirawaraporn, W.; Taylor, P.; Walkinshaw, M. D.; Yuthavong, Y. Insights into Antifolate Resistance from Malarial DHFR-TS Structures. *Nat. Struct. Biol.* **2003**, *10*, 357-365.

(13) Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. *Methods Enzymol.* **1997**, *276*, 307-326.

(14) Winn, M. D.; Ballard, C. C.; Cowtan, K. D.; Dodson, E. J.; Emsley, P.; Evans, P. R.; Keegan, R. M.; Krissinel, E. B.; Leslie, A. G.; McCoy, A.; McNicholas, S. J.; Murshudov, G. N.; Pannu, N. S.; Potterton, E. A.; Powell, H. R.; Read, R. J.; Vagin, A.; Wilson, K. S. Overview of the CCP4 Suite and Current Developments. *Acta Crystallogr. Sect. D: Biol. Crystallogr.* **2011**, *67*, 235-242.

(15) McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser Crystallographic Software. *J. Appl. Crystallogr.* **2007**, *40*, 658-674.

(16) Murshudov, G. N.; Skubak, P.; Lebedev, A. A.; Pannu, N. S.; Steiner, R. A.; Nicholls, R. A.; Winn, M. D.; Long, F.; Vagin, A. A. REFMAC5 for the Refinement of Macromolecular Crystal Structures. *Acta Crystallogr. Sect. D: Biol. Crystallogr.* **2011**, *67*, 355-367.

(17) Emsley, P.; Cowtan, K. Coot: Model-Building Tools for Molecular Graphics. *Acta Crystallogr. Sect. D: Biol. Crystallogr.* **2004**, *60*, 2126-2132

(18) Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and Development of Coot. *Acta Crystallogr. Sect. D: Biol. Crystallogr.* **2010**, *66*, 486-501.

(19) Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: a Program to Check the Stereochemical Quality of Protein structures. *J. Appl. Crystallogr.* **1993**, *26*, 283-291.

(20) Yuthavong, Y.; Tarnchompoo, B.; Vilaiwan, T.; Chitnumsub, P.; Kamchonwongpaisan, S.; Charman, S. A.; McLennan, D. N.; White, K. L.; Vivas, L.; Bongard, E.; Thongphanchang, C.; Taweechai, S.; Vanichthananakul, J.; Rattanajak, R.; Arwon, U.; Fantauzzi, P.; Yuvaniyama, J.; Charman, W. N.; Matthews, D. Malarial Dihydrofolate Reductase as a Paradigm for Drug Development against a Resistance-Compromised Target. *Proc. Natl. Acad. Sci. U.S.A.* **2012**, *109*, 16823-16828.

(21) Vagin, A.; Teplyakov, A. Molecular Replacement with MOLREP. *Acta Crystallogr. Sect. D: Biol. Crystallogr.* **2010**, *66*, 22-25.

(22) Lovell, S. C.; Davis, I. W.; Arendall, W. B., 3rd; de Bakker, P. I.; Word, J. M.; Prisant, M. G.; Richardson, J. S.; Richardson, D. C. Structure Validation by Coα Geometry: φ,ψ and Cβ Deviation. *Proteins* **2003**, *50*, 437-450.